Vizgen laid off an unspecified number of employees as part of a strategic reorganization, according to company statements and employee reports. The spatial technology company said it is investing in growth areas including neuro discovery for academia and biopharma, while leveraging manufacturing partners to complement its internal capabilities. The restructuring follows a $48 million funding round earlier in the year intended to expand commercial operations, global capability, and the pipeline. Former staff described reductions across both R&D and commercial functions. The move underlines how spatial multiomics companies are adjusting cost bases while prioritizing near-term commercial and partnership execution.